Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson's disease.

IF 5.7 4区 生物学 Q1 BIOLOGY
Bioscience trends Pub Date : 2025-03-06 Epub Date: 2025-02-09 DOI:10.5582/bst.2024.01369
Chien-Tai Hong, Chen-Chih Chung, Yi-Chen Hsieh, Lung Chan
{"title":"Plasma extracellular vesicle pathognomonic proteins as the biomarkers of the progression of Parkinson's disease.","authors":"Chien-Tai Hong, Chen-Chih Chung, Yi-Chen Hsieh, Lung Chan","doi":"10.5582/bst.2024.01369","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder for which reliable blood biomarkers to predict disease progression remain elusive. Plasma extracellular vesicles (EVs) have gained attention as a promising biomarker platform due to their stability and ability to cross the blood-brain barrier. This study explored the potential of EV-cargo proteins, specifically α-synuclein, tau, and β-amyloid, as biomarkers of PD progression. A cohort of 55 people with PD (PwP) and 58 healthy controls (HCs) underwent annual assessments of plasma EV proteins, cognition, and motor symptoms. EVs were isolated and validated using standardized methods, with pathognomonic proteins quantified via immunomagnetic reduction assays. Associations between biomarker changes and clinical symptom progression were analyzed. Over an average of 3.96 visits for PwP and 2.25 visits for HCs, PwP exhibited a distinct pattern of plasma EV protein changes linked to motor symptom progression, particularly in the Unified PD Rating Scale (UPDRS) part II score. Notably, changes in plasma EV α-synuclein levels were significantly correlated with changes in motor and cognitive symptoms, suggesting its central role in disease progression. These findings highlight the potential of plasma EV biomarkers, especially α-synuclein, as indicators of ongoing pathogenesis and as candidates for evaluating α-synuclein-targeted therapies in PD.</p>","PeriodicalId":8957,"journal":{"name":"Bioscience trends","volume":" ","pages":"116-124"},"PeriodicalIF":5.7000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioscience trends","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.5582/bst.2024.01369","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder for which reliable blood biomarkers to predict disease progression remain elusive. Plasma extracellular vesicles (EVs) have gained attention as a promising biomarker platform due to their stability and ability to cross the blood-brain barrier. This study explored the potential of EV-cargo proteins, specifically α-synuclein, tau, and β-amyloid, as biomarkers of PD progression. A cohort of 55 people with PD (PwP) and 58 healthy controls (HCs) underwent annual assessments of plasma EV proteins, cognition, and motor symptoms. EVs were isolated and validated using standardized methods, with pathognomonic proteins quantified via immunomagnetic reduction assays. Associations between biomarker changes and clinical symptom progression were analyzed. Over an average of 3.96 visits for PwP and 2.25 visits for HCs, PwP exhibited a distinct pattern of plasma EV protein changes linked to motor symptom progression, particularly in the Unified PD Rating Scale (UPDRS) part II score. Notably, changes in plasma EV α-synuclein levels were significantly correlated with changes in motor and cognitive symptoms, suggesting its central role in disease progression. These findings highlight the potential of plasma EV biomarkers, especially α-synuclein, as indicators of ongoing pathogenesis and as candidates for evaluating α-synuclein-targeted therapies in PD.

血浆细胞外囊泡病理特异蛋白作为帕金森病进展的生物标志物
帕金森病(PD)是一种进行性神经退行性疾病,可靠的血液生物标志物预测疾病进展仍然难以捉摸。血浆细胞外囊泡(EVs)由于其稳定性和穿越血脑屏障的能力而成为一种有前途的生物标志物平台。本研究探讨了ev货物蛋白,特别是α-突触核蛋白、tau蛋白和β-淀粉样蛋白作为PD进展的生物标志物的潜力。55名PD患者(PwP)和58名健康对照者(hc)每年接受血浆EV蛋白、认知和运动症状的评估。采用标准化方法分离和验证ev,并通过免疫磁还原法定量致病蛋白。分析生物标志物变化与临床症状进展之间的关系。PwP患者平均就诊3.96次,hc患者平均就诊2.25次,PwP患者表现出与运动症状进展相关的血浆EV蛋白变化的独特模式,特别是在统一PD评定量表(UPDRS)第二部分评分中。值得注意的是,血浆EV α-突触核蛋白水平的变化与运动和认知症状的变化显著相关,提示其在疾病进展中的核心作用。这些发现突出了血浆EV生物标志物,特别是α-突触核蛋白,作为正在进行的发病机制的指标和评估α-突触核蛋白靶向治疗PD的候选物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
13.60
自引率
1.80%
发文量
47
审稿时长
>12 weeks
期刊介绍: BioScience Trends (Print ISSN 1881-7815, Online ISSN 1881-7823) is an international peer-reviewed journal. BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信